WO2010003313A1 - 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 - Google Patents
埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 Download PDFInfo
- Publication number
- WO2010003313A1 WO2010003313A1 PCT/CN2009/000773 CN2009000773W WO2010003313A1 WO 2010003313 A1 WO2010003313 A1 WO 2010003313A1 CN 2009000773 W CN2009000773 W CN 2009000773W WO 2010003313 A1 WO2010003313 A1 WO 2010003313A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- hydrochloride
- pharmaceutical composition
- day
- tumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09793788.2A EP2392576B1 (en) | 2008-07-08 | 2009-07-07 | Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
CA2730311A CA2730311A1 (en) | 2008-07-08 | 2009-07-07 | Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof |
NZ590334A NZ590334A (en) | 2008-07-08 | 2009-07-07 | ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF |
CN2009801006661A CN101878218B (zh) | 2008-07-08 | 2009-07-07 | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 |
JP2011516948A JP5719770B2 (ja) | 2008-07-08 | 2009-07-07 | 塩酸イコチニブ、合成物、結晶学的形態、併用薬及びその用途 |
AU2009267683A AU2009267683B2 (en) | 2008-07-08 | 2009-07-07 | Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
US13/003,216 US8822482B2 (en) | 2008-07-08 | 2009-07-07 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof |
HK10111360.7A HK1145319A1 (en) | 2008-07-08 | 2010-12-07 | Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
IL210447A IL210447A0 (en) | 2008-07-08 | 2011-01-03 | Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof |
US14/448,070 US9359370B2 (en) | 2008-07-08 | 2014-07-31 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810132631 | 2008-07-08 | ||
CN200810132631.3 | 2008-07-08 | ||
CN200810132458.7 | 2008-07-17 | ||
CN200810132458 | 2008-07-17 | ||
CN200810188272.3 | 2008-12-23 | ||
CN200810188272 | 2008-12-23 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/003,216 A-371-Of-International US8822482B2 (en) | 2008-07-08 | 2009-07-07 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof |
US14/448,070 Continuation US9359370B2 (en) | 2008-07-08 | 2014-07-31 | Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010003313A1 true WO2010003313A1 (zh) | 2010-01-14 |
WO2010003313A8 WO2010003313A8 (zh) | 2010-04-22 |
Family
ID=41506667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000773 WO2010003313A1 (zh) | 2008-07-08 | 2009-07-07 | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8822482B2 (zh) |
EP (1) | EP2392576B1 (zh) |
JP (2) | JP5719770B2 (zh) |
KR (1) | KR20110031370A (zh) |
CN (5) | CN104530061B (zh) |
AU (1) | AU2009267683B2 (zh) |
CA (1) | CA2730311A1 (zh) |
HK (1) | HK1145319A1 (zh) |
IL (1) | IL210447A0 (zh) |
NZ (1) | NZ590334A (zh) |
WO (1) | WO2010003313A1 (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013064128A1 (zh) | 2011-10-31 | 2013-05-10 | 浙江贝达药业有限公司 | 埃克替尼和盐酸埃克替尼的制备方法及其中间体 |
JP2013531016A (ja) * | 2010-07-14 | 2013-08-01 | ジャージャン ベータ ファーマ インコーポレイテッド | c−METチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体 |
WO2013143057A1 (zh) * | 2012-03-26 | 2013-10-03 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及用途 |
JP2013544843A (ja) * | 2010-12-01 | 2013-12-19 | ニーキ ファーマ インコーポレイテッド | 難治性癌を治療するための方法 |
JP2014510704A (ja) * | 2010-12-20 | 2014-05-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 新規医薬組成物 |
JP2014098048A (ja) * | 2010-03-19 | 2014-05-29 | Boston Biomedical Inc | がん幹細胞を標的とするための新規の化合物および組成物 |
WO2014198210A1 (en) * | 2013-06-09 | 2014-12-18 | Betta Pharmaceuticals Co., Ltd | Polymorph forms of icotinib maleate and uses thereof |
WO2014198212A1 (en) * | 2013-06-09 | 2014-12-18 | Betta Pharmaceuticals Co.,Ltd | Polymorphic forms of icotinib and uses thereof |
WO2015051763A1 (zh) | 2013-10-11 | 2015-04-16 | 贝达药业股份有限公司 | 一种含埃克替尼的皮肤外用药物组合物及其应用 |
US9688687B2 (en) | 2013-06-09 | 2017-06-27 | Betta Pharmaceuticals Co., Ltd. | Polymorphic forms of icotinib phosphate and uses thereof |
CN109512779A (zh) * | 2013-10-11 | 2019-03-26 | 贝达药业股份有限公司 | 一种含埃克替尼的皮肤外用药物组合物及其应用 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104530061B (zh) * | 2008-07-08 | 2017-05-10 | 贝达药业股份有限公司 | 埃克替尼盐酸盐晶型、药物组合物和用途 |
WO2014028914A1 (en) * | 2012-08-17 | 2014-02-20 | Beta Pharma, Inc. | Deuterated icotinib derivatives |
WO2014073989A1 (en) * | 2012-11-12 | 2014-05-15 | Callaghan Innovation Research Limited | Salt and polymorphic forms of (3r,4s)-l-((4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4(methylthiomethyl)pyrodin-3-ol(mtdia) |
JP5955396B2 (ja) * | 2012-12-28 | 2016-07-20 | ベータ ファーマシューティカルズ カンパニー リミテッド | イコチニブ、イコチニブ塩酸塩、及びそれらの中間体の製造方法 |
CN104470526B (zh) * | 2013-06-09 | 2016-07-13 | 贝达药业股份有限公司 | 埃克替尼磷酸盐的晶型及其用途 |
CN104470929B (zh) * | 2013-06-09 | 2018-11-30 | 贝达药业股份有限公司 | 埃克替尼的晶型及其应用 |
CN104487443B (zh) * | 2013-06-09 | 2016-03-23 | 贝达药业股份有限公司 | 埃克替尼马来酸盐的晶型及其用途 |
CN103784412A (zh) * | 2014-01-15 | 2014-05-14 | 青岛市肿瘤医院 | 一种盐酸埃克替尼分散片及其制备方法 |
CN103860521A (zh) * | 2014-03-05 | 2014-06-18 | 王栾秋 | 盐酸埃克替尼胶囊组合物及其制备方法 |
CN106924739B (zh) * | 2017-03-10 | 2022-07-29 | 上海交通大学医学院 | Egfr抑制剂在制备治疗muc1阳性肿瘤药物中的应用 |
CN111909163B (zh) * | 2020-04-21 | 2022-02-01 | 南开大学 | 具有ido1抑制功能的喹啉胺类化合物及其制备方法 |
CN111362957B (zh) * | 2020-04-21 | 2022-02-18 | 上海百利佳生医药科技有限公司 | 一种埃克替尼关键中间体的制备方法 |
CN111763214B (zh) * | 2020-08-10 | 2022-03-15 | 苏州富士莱医药股份有限公司 | 一种埃克替尼的制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1534026A (zh) * | 2002-03-28 | 2004-10-06 | �Ϳ���ҽҩ��˾ | 新型作为酪氨酸激酶抑制剂的稠合的喹唑啉衍生物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002338577A (ja) | 2001-05-15 | 2002-11-27 | Orient Chem Ind Ltd | 分子内架橋クラウンエーテル環を有するフタロシアニン誘導体及びその製造方法 |
CN104530061B (zh) * | 2008-07-08 | 2017-05-10 | 贝达药业股份有限公司 | 埃克替尼盐酸盐晶型、药物组合物和用途 |
-
2009
- 2009-07-07 CN CN201410828693.3A patent/CN104530061B/zh active Active
- 2009-07-07 JP JP2011516948A patent/JP5719770B2/ja active Active
- 2009-07-07 AU AU2009267683A patent/AU2009267683B2/en not_active Ceased
- 2009-07-07 CN CN201410833295.0A patent/CN104592242B/zh active Active
- 2009-07-07 CN CN201210438377.6A patent/CN102911179B/zh active Active
- 2009-07-07 NZ NZ590334A patent/NZ590334A/xx not_active IP Right Cessation
- 2009-07-07 US US13/003,216 patent/US8822482B2/en not_active Expired - Fee Related
- 2009-07-07 EP EP09793788.2A patent/EP2392576B1/en not_active Not-in-force
- 2009-07-07 CN CN2009801006661A patent/CN101878218B/zh active Active
- 2009-07-07 WO PCT/CN2009/000773 patent/WO2010003313A1/zh active Application Filing
- 2009-07-07 CN CN201210437345.4A patent/CN103254204B/zh active Active
- 2009-07-07 CA CA2730311A patent/CA2730311A1/en not_active Abandoned
- 2009-07-07 KR KR1020117002841A patent/KR20110031370A/ko not_active Application Discontinuation
-
2010
- 2010-12-07 HK HK10111360.7A patent/HK1145319A1/xx unknown
-
2011
- 2011-01-03 IL IL210447A patent/IL210447A0/en unknown
-
2014
- 2014-07-31 US US14/448,070 patent/US9359370B2/en active Active
-
2015
- 2015-02-13 JP JP2015026902A patent/JP2015110649A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1534026A (zh) * | 2002-03-28 | 2004-10-06 | �Ϳ���ҽҩ��˾ | 新型作为酪氨酸激酶抑制剂的稠合的喹唑啉衍生物 |
CN1305860C (zh) | 2002-03-28 | 2007-03-21 | 浙江贝达药业有限公司 | 新型作为酪氨酸激酶抑制剂的稠合的喹唑啉衍生物 |
Non-Patent Citations (5)
Title |
---|
ALCOCK, NATHANIEL W ET AL.: "Transition-metal complexes of superstructured cyclidene macrobicycles: structural features and their chemical consequences. 3. Cyclidenes with long polymethylene bridges", INORGANIC CHEMISTRY, vol. 29, no. 14, 1990, pages 2599 - 2607, XP008139657 * |
CALDERON, VERONICA ET AL.: "Synthesis and characterization of new aromatic polyamides bearing crown ethers or their dipodal counterparts in the pendant structure. I. Benzo-12-crown-4 and ortho-bis(2-ethoxyethoxy)benzene", JOURNAL OF POLYMER SCIENCE, PART A: POLYMER CHEMISTRY, vol. 44, no. 7, 2006, pages 2270 - 2281, XP008139658 * |
GUAN, ZHONGMIN ET AL.: "Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry", RAPID COMMUNICATIONS IN MASS SPECTROMETRY, vol. 22, no. 14, 6 June 2008 (2008-06-06), pages 2176 - 2184, XP008139660 * |
See also references of EP2392576A4 |
YAND, CAILING ET AL.: "Effect of icotinib on human tongue carcinoma a cell line Tca8113 proliferation", JOURNAL OFZHENGZHOU UNIVERSITY (MEDICAL SCIENCES), vol. 43, no. 4, 20 July 2008 (2008-07-20), pages 701 - 703, XP008139977 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014098048A (ja) * | 2010-03-19 | 2014-05-29 | Boston Biomedical Inc | がん幹細胞を標的とするための新規の化合物および組成物 |
JP2013531016A (ja) * | 2010-07-14 | 2013-08-01 | ジャージャン ベータ ファーマ インコーポレイテッド | c−METチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体 |
JP2013544843A (ja) * | 2010-12-01 | 2013-12-19 | ニーキ ファーマ インコーポレイテッド | 難治性癌を治療するための方法 |
JP2017137299A (ja) * | 2010-12-20 | 2017-08-10 | ノバルティス アーゲー | 新規医薬組成物 |
JP2014510704A (ja) * | 2010-12-20 | 2014-05-01 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー2、リミテッド | 新規医薬組成物 |
US9085588B2 (en) | 2011-10-31 | 2015-07-21 | Betta Pharmaceuticals Co., Ltd. | Methods of preparing icotinib and icotinib hydrochloride, and intermediates thereof |
CN105237510A (zh) * | 2011-10-31 | 2016-01-13 | 贝达药业股份有限公司 | 埃克替尼和盐酸埃克替尼的制备方法及其中间体 |
CN104024262B (zh) * | 2011-10-31 | 2017-03-22 | 贝达药业股份有限公司 | 埃克替尼和盐酸埃克替尼的制备方法及其中间体 |
CN104024262A (zh) * | 2011-10-31 | 2014-09-03 | 贝达药业股份有限公司 | 埃克替尼和盐酸埃克替尼的制备方法及其中间体 |
WO2013064128A1 (zh) | 2011-10-31 | 2013-05-10 | 浙江贝达药业有限公司 | 埃克替尼和盐酸埃克替尼的制备方法及其中间体 |
WO2013143057A1 (zh) * | 2012-03-26 | 2013-10-03 | 中国科学院福建物质结构研究所 | 喹唑啉衍生物及用途 |
US9505774B2 (en) | 2013-06-09 | 2016-11-29 | Betta Pharmaceuticals Co., Ltd. | Polymorphic forms of icotinib maleate and uses thereof |
EP3008070A1 (en) * | 2013-06-09 | 2016-04-20 | Betta Pharmaceuticals Co., Ltd. | Polymorph forms of icotinib maleate and uses thereof |
EP3008070A4 (en) * | 2013-06-09 | 2016-08-10 | Betta Pharmaceuticals Co Ltd | POLYMORPHIC FORMS OF ICOTINIB MALEATE AND USES THEREOF |
WO2014198212A1 (en) * | 2013-06-09 | 2014-12-18 | Betta Pharmaceuticals Co.,Ltd | Polymorphic forms of icotinib and uses thereof |
US9611272B2 (en) | 2013-06-09 | 2017-04-04 | Betta Pharmaceuticals Co., Ltd. | Polymorphic forms of icotinib and uses thereof |
AU2014280711B2 (en) * | 2013-06-09 | 2017-04-13 | Betta Pharmaceuticals Co.,Ltd | Polymorphic forms of Icotinib and uses thereof |
US9688687B2 (en) | 2013-06-09 | 2017-06-27 | Betta Pharmaceuticals Co., Ltd. | Polymorphic forms of icotinib phosphate and uses thereof |
WO2014198210A1 (en) * | 2013-06-09 | 2014-12-18 | Betta Pharmaceuticals Co., Ltd | Polymorph forms of icotinib maleate and uses thereof |
TWI596098B (zh) * | 2013-06-09 | 2017-08-21 | 貝達藥業股份有限公司 | 埃克替尼馬來酸鹽的晶型及其用途 |
WO2015051763A1 (zh) | 2013-10-11 | 2015-04-16 | 贝达药业股份有限公司 | 一种含埃克替尼的皮肤外用药物组合物及其应用 |
TWI630921B (zh) * | 2013-10-11 | 2018-08-01 | 貝達藥業股份有限公司 | 含埃克替尼的皮膚外用藥物組合物及其應用 |
CN109512779A (zh) * | 2013-10-11 | 2019-03-26 | 贝达药业股份有限公司 | 一种含埃克替尼的皮肤外用药物组合物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN104592242A (zh) | 2015-05-06 |
CN101878218B (zh) | 2013-01-02 |
IL210447A0 (en) | 2011-03-31 |
CN102911179A (zh) | 2013-02-06 |
CA2730311A1 (en) | 2010-01-14 |
AU2009267683B2 (en) | 2014-04-03 |
CN104530061B (zh) | 2017-05-10 |
CN103254204A (zh) | 2013-08-21 |
WO2010003313A8 (zh) | 2010-04-22 |
CN101878218A (zh) | 2010-11-03 |
US20110182882A1 (en) | 2011-07-28 |
CN103254204B (zh) | 2014-10-22 |
KR20110031370A (ko) | 2011-03-25 |
JP2011527291A (ja) | 2011-10-27 |
JP5719770B2 (ja) | 2015-05-20 |
JP2015110649A (ja) | 2015-06-18 |
NZ590334A (en) | 2012-12-21 |
US9359370B2 (en) | 2016-06-07 |
EP2392576A1 (en) | 2011-12-07 |
CN102911179B (zh) | 2015-04-08 |
EP2392576A4 (en) | 2012-04-11 |
EP2392576B1 (en) | 2016-02-17 |
US8822482B2 (en) | 2014-09-02 |
CN104592242B (zh) | 2017-01-25 |
AU2009267683A1 (en) | 2010-01-14 |
HK1145319A1 (en) | 2011-04-15 |
CN104530061A (zh) | 2015-04-22 |
US20140343082A1 (en) | 2014-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010003313A1 (zh) | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 | |
JP7036798B2 (ja) | キナゾリン誘導体の塩の結晶 | |
JP2020526593A (ja) | N−フェニル−2−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法 | |
TWI535724B (zh) | 埃克替尼磷酸鹽的新晶型及其用途 | |
WO2020147838A1 (zh) | 一种egfr抑制剂的盐、晶型及其制备方法 | |
CN110407839B (zh) | 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用 | |
TWI529174B (zh) | 埃克替尼的晶型及其應用 | |
EP3008070B9 (en) | Polymorph forms of icotinib maleate and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980100666.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09793788 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009267683 Country of ref document: AU Ref document number: 590334 Country of ref document: NZ Ref document number: 12011500036 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2730311 Country of ref document: CA Ref document number: 2011516948 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 540/KOLNP/2011 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009267683 Country of ref document: AU Date of ref document: 20090707 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20117002841 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13003216 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009793788 Country of ref document: EP |